ALSO NOTED: Nexavar OK'd for use against liver cancer; Japan's Olympus to buy Gyrus in $1.9 billion deal;

> Bayer and Onyx Pharmaceuticals got the FDA's nod to market Nexavar to treat liver cancer; the drug already is used against kidney cancer. Report

> Surgical equipment maker Gyrus recommended that its shareholders accept a $1.9 billion cash tender offer from Olympus, the Japanese camera company. Report

> Schering-Plough has wrapped up its acquisition of Organon BioSciences. Report

> Sales of over-the-counter cold meds for kids have fallen sharply since an FDA panel concluded they shouldn't be used in children younger than 6. Report

> India's Plethico Pharma is buying U.S.-based Natrol, a manufacturer and marketer of nutritional products, for $80.7 million. Report

> A Dallas whistleblower has implicated a multitude of surgical suppliers in a Medicare-fraud suit just unsealed in federal court. Report

And Finally... The much talked-about Baby Boomer generation is heading into their 50s--and they're looking to biotechnology to not only to extend their lives, but to make their later years better. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.